These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26994242)

  • 61. Malignant hyperthermia: update on susceptibility testing.
    Litman RS; Rosenberg H
    JAMA; 2005 Jun; 293(23):2918-24. PubMed ID: 15956637
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The use of guidelines to assess the risk of malignant hyperthermia in individuals with an RYR1 variant.
    Voermans NC; Yang C; Schouten M; Girard T; Stowell K; Riazi S; Kamsteeg EJ; Snoeck M
    Neuromuscul Disord; 2024 Feb; 35():40-41. PubMed ID: 38007345
    [No Abstract]   [Full Text] [Related]  

  • 63. In Reply.
    Hopkins PM; Fiszer D; Shaw MA; Roiz de Sa D
    Anesthesiology; 2016 Feb; 124(2):511. PubMed ID: 26785434
    [No Abstract]   [Full Text] [Related]  

  • 64. [Malignant hyperthermia].
    Metterlein T; Schuster F; Graf BM; Anetseder M
    Anaesthesist; 2014 Dec; 63(12):908-18. PubMed ID: 25384957
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Functional properties of RYR1 mutations identified in Swedish patients with malignant hyperthermia and central core disease.
    Vukcevic M; Broman M; Islander G; Bodelsson M; Ranklev-Twetman E; Müller CR; Treves S
    Anesth Analg; 2010 Jul; 111(1):185-90. PubMed ID: 20142353
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Hotline for malignant hyperthermia. New telephone number for the German nationwide 24 h service center: 08221/9600].
    Klingler W; Lehmann-Horn F; Schulte-Sasse U
    Anaesthesist; 2011 Feb; 60(2):172-4. PubMed ID: 21308355
    [No Abstract]   [Full Text] [Related]  

  • 67. Congenital ptosis, scoliosis, and malignant hyperthermia susceptibility in siblings with recessive RYR1 mutations.
    AlBakri A; Karaoui M; Alkuraya FS; Khan AO
    J AAPOS; 2015 Dec; 19(6):577-9. PubMed ID: 26691049
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Effect of chlorocresol vs caffeine on muscle contracture in malignant hyperthermia susceptible patients].
    Ben-Abraham R; Krivosic-Horber RM; Haudcoeur G; Perel A; Adnet PJ
    Harefuah; 1997 Jun; 132(12):839-41, 911. PubMed ID: 9264187
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Nonanesthetic malignant hyperthermia.
    Lehmann-Horn F; Klingler W; Jurkat-Rott K
    Anesthesiology; 2011 Nov; 115(5):915-7. PubMed ID: 21878807
    [No Abstract]   [Full Text] [Related]  

  • 70. PharmGKB summary: very important pharmacogene information for RYR1.
    Alvarellos ML; Krauss RM; Wilke RA; Altman RB; Klein TE
    Pharmacogenet Genomics; 2016 Mar; 26(3):138-44. PubMed ID: 26709912
    [No Abstract]   [Full Text] [Related]  

  • 71. Next-generation DNA sequencing of a Swedish malignant hyperthermia cohort.
    Broman M; Kleinschnitz I; Bach JE; Rost S; Islander G; Müller CR
    Clin Genet; 2015 Oct; 88(4):381-5. PubMed ID: 25256590
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical utility gene card for: malignant hyperthermia.
    Rosenberg H; Rueffert H
    Eur J Hum Genet; 2011 Jun; 19(6):. PubMed ID: 21248738
    [No Abstract]   [Full Text] [Related]  

  • 73. Confirmation of nonanesthetic-induced malignant hyperthermia.
    Larach MG; Allen GC; Rosenberg H
    Anesthesiology; 2012 Jun; 116(6):1398-9; author reply 1399-400. PubMed ID: 22617205
    [No Abstract]   [Full Text] [Related]  

  • 74. Special article: Future directions in malignant hyperthermia research and patient care.
    Hirshey Dirksen SJ; Larach MG; Rosenberg H; Brandom BW; Parness J; Lang RS; Gangadharan M; Pezalski T
    Anesth Analg; 2011 Nov; 113(5):1108-19. PubMed ID: 21709147
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Delayed postoperative rhabdomyolysis in a patient subsequently diagnosed as malignant hyperthermia susceptible.
    McKenney KA; Holman SJ
    Anesthesiology; 2002 Mar; 96(3):764-5. PubMed ID: 11873057
    [No Abstract]   [Full Text] [Related]  

  • 76. Multicentre evaluation of ryanodine contracture testing in malignant hyperthermia. The European Malignant Hyperthermia Group.
    Hopkins PM; Hartung E; Wappler F
    Br J Anaesth; 1998 Mar; 80(3):389-94. PubMed ID: 9623444
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Oxygen Consumption and Basal Metabolic Rate as Markers of Susceptibility to Malignant Hyperthermia and Heat Stroke.
    Serano M; Pietrangelo L; Paolini C; Guarnier FA; Protasi F
    Cells; 2022 Aug; 11(16):. PubMed ID: 36010545
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A genetic mystery in malignant hyperthermia 'solved'?
    Schiemann AH; Bjorksten AR; Gillies RL; Hockey BM; Ball C; Pollock N; Bulger T; Stowell KM
    Br J Anaesth; 2018 Sep; 121(3):681-682. PubMed ID: 30115273
    [No Abstract]   [Full Text] [Related]  

  • 79. The biochemistry of malignant hyperthermia: recent concepts.
    Joffe M; Savage N; Silove M
    Int J Biochem; 1992 Mar; 24(3):387-98. PubMed ID: 1312953
    [No Abstract]   [Full Text] [Related]  

  • 80. Pharmacogenomics of inhalational anesthetic agents.
    Nair AS
    Med Gas Res; 2019; 9(1):52-53. PubMed ID: 30950419
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.